Opus Genetics (IRD) Cash from Financing Activities (2011 - 2026)
Opus Genetics (IRD) posted quarterly Cash from Financing Activities of $27.6 million for Q1 2026, up 34.84% year-over-year from $20.5 million in Q1 2025, and up 14.46% quarter-over-quarter from $24.1 million in Q4 2025.
Opus Genetics (IRD) Cash from Financing Activities (2011 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Cash from Financing Activities for 14 consecutive years, with $27.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 34.84% year-over-year to $27.6 million; the TTM figure through Mar 2026 stood at $57.2 million (up 156.58% YoY), while the FY2025 annual figure was $50.0 million, up 1095.01% from the prior year.
- Cash from Financing Activities grew to $27.6 million in Q1 2026 per IRD's latest filing, from $24.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $27.6 million in Q1 2026 and bottomed at -$83000.0 in Q4 2024.
- Historically, Cash from Financing Activities has averaged $6.3 million across 5 years, with a median of $1.6 million in 2022.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 30125.0% — and 2024, when it plunged 102.3%.
- Opus Genetics' Cash from Financing Activities stood at -$12000.0 in 2022, then soared by 30125.0% to $3.6 million in 2023, then tumbled by 102.3% to -$83000.0 in 2024, then soared by 29146.99% to $24.1 million in 2025, then climbed by 14.46% to $27.6 million in 2026.
- Business Quant data shows IRD's Cash from Financing Activities at $27.6 million in Q1 2026, $24.1 million in Q4 2025, and $4.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | 40.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.90 Mn |
| Jun 30, 2026 | 40.90 Mn |
| Mar 31, 2026 | 27.60 Mn |
| Mar 31, 2026 | 27.60 Mn |
| Dec 31, 2025 | 24.11 Mn |
| Dec 31, 2025 | 24.11 Mn |
| Sep 30, 2025 | 4.54 Mn |
| Sep 30, 2025 | 4.54 Mn |
| Jun 30, 2025 | 906,000.00 |
| Jun 30, 2025 | 906,000.00 |
| Mar 31, 2025 | 20.47 Mn |
| Mar 31, 2025 | 20.47 Mn |
| Dec 31, 2024 | -83,000.00 |
| Dec 31, 2024 | -83,000.00 |
| Sep 30, 2024 | 353,000.00 |
| Sep 30, 2024 | 353,000.00 |
| Jun 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 1.54 Mn |
| Mar 31, 2024 | 2.38 Mn |
| Mar 31, 2024 | 2.38 Mn |